Эффективность венлафаксина при хроническом болевом синдроме

DOI: https://doi.org/10.29296/25877305-2019-04-06
Скачать статью в PDF
Номер журнала: 
4
Год издания: 
2019

Т. Вазагаева, кандидат медицинских наук, Э. Кварианташвили Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского, Москва E-mail: vazagaeva@mail.ru

В настоящее время при лечении различных хронических болевых синдромов наряду с анальгетиками рекомендуется применять адъювантные препараты. К числу антидепрессантов с доказанным анальгетическим действием относится венлафаксин, обладающий более благоприятным профилем переносимости, чем трициклические антидепрессанты, традиционно используемые при лечении пациентов с хронической болью (ХБ). Во многих исследованиях показана высокая эффективность венлафаксина при терапии нейропатической боли, в то время как эффективность препарата при других видах ХБ изучена недостаточно. Хотя в большинстве современных руководств венлафаксин не рассматривается в качестве препарата 1-й линии при лечении ХБ, имеются основания для его применения в клинической практике во многих случаях, например при плохой переносимости или наличии противопоказаний к приему других антидепрессантов и противосудорожных препаратов. Для расширения и дополнения сведений об особенностях и спектре анальгетической активности венлафаксина необходимы дальнейшие исследования.
Ключевые слова: 
терапия
хронический болевой синдром
венлафаксин
Для цитирования
Вазагаева Т., Кварианташвили Э. Эффективность венлафаксина при хроническом болевом синдроме . Врач, 2019; (4): 35-42 https://doi.org/10.29296/25877305-2019-04-06

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Goldberg D., McGee S. Pain as a global public health priority // BMC Public Health. – 2011; 11: 770. DOI: 10.1186/1471-2458-11-770.
  2. Rice A., Smith B., Blyth F. Pain and the global burden of disease // Pain. – 2016; 157 (4): 791–6. DOI: 10.1097/j.pain.0000000000000454.
  3. Finnerup N., Scholz J., Attal N. et al. Neuropathic pain needs systematic classification // Eur. J. Pain. – 2013; 17: 953–6. DOI: 10.1002/j.1532-2149.2012.00282.x.
  4. Rief W., Kaasa S., Jensen R.et al. The need to revise pain diagnoses in ICD-11 // Pain. – 2010; 149: 169–70. DOI: 10.1016/j.pain.2010.03.006.
  5. Treede R., Rief W., Barke A. et al. A classification of chronic pain for ICD-11 // Pain. – 2015; 156 (6): 1003–7. DOI: 10.1097/j.pain.0000000000000160.
  6. Treede R., Rief W., Barke A.et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11) // Pain. – 2019; 160 (1): 19–27. DOI: 10.1097/j.pain.0000000000001384.
  7. Nicholas M., Vlaeyen J., Rief W. et al. The IASP Taskforce for the Classification of Chronic pain. The IASP classification of chronic pain for ICD-11: chronic primary pain // Pain. – 2019; 160: 28–37. DOI: 10.1097/j.pain.0000000000001390.
  8. Khouzam H. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics // Postgrad Med. – 2016; 128 (3): 323–30. DOI: 10.1080/00325481.2016.1147925.
  9. Jann M., Slade J. Antidepressant agents for the treatment of chronic pain and depression // Pharmacotherapy. – 2007; 27: 1571–87. DOI: 10.1592/phco.27.11.1571.
  10. Katzman M., Pawluk E., Tsirgielis D. et al. Beyond chronic pain: how best to treat psychological comorbidities // J. Fam. Pract. – 2014; 63: 260–4.
  11. Rico-Villademoros F., Slim M., Calandre E. Amitriptyline for the treatment of fibromyalgia: a comprehensive review // Expert Rev. Neurother. – 2015; 15: 1123–50. DOI: 10.1586/14737175.2015.
  12. Shultz E., Malone D. Jr. A practical approach to prescribing antidepressants // Cleve Clin. J. Med. – 2013; 80: 625–31. DOI: 10.3949/ccjm.80a.
  13. Saarto T., Wiffen P. Antidepressants for neuropathic pain // Cochrane Database Syst. Rev. – 2005; 3: CD005454. DOI: 10.1002/14651858.CD005454.pub2.
  14. Gershon M., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders // Gastroenterology. – 2007; 132: 397–414. DOI: 10.1053/j.gastro.2006.11.002.
  15. Макаров С.А., Чурюканов М.В., Чурюканов В.В. Антидепрессанты в лечении боли // Росс. журн. боли. – 2016; 3–4 (51): 74–85 [Makarov S.A., Churukanov M.V., Churukanov V.V. Antidepressants in the treatment of pain // Ross. zhurn. boli. – 2016; 3–4 (51): 74–85 (in Russ.)].
  16. Miura N., Saito T., Taira T. et al. Risk factors for QT prolongation associated with acute psychotropic drug overdose // Am. J. Emerg. Med. – 2015; 33: 142–9. DOI: 10.1016/j.ajem.2014.09.048.
  17. Rintala D., Holmes S., Courtade D. et al. Comparison of the effectiveness of amitriptyline and gabapentin in chronic neuropathic pain in persons with spinal cord injury // Arch. Phys. Med. Rehabil. – 2007; 88: 1547–60. DOI: 10.1016/j.apmr.2007.07.038.
  18. Sultana J., Spina E., Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety // Expert. Opin. Drug Metab. Toxicol. – 2015; 11: 883–92. DOI: 10.1517/17425255.2015.1021684.
  19. Rodieux F., Piguet V., Berney P. et al. Prescription of antidepressants in the treatment of pain: role of pharmacogenetics // Rev. Med. Suisse. – 2015; 11: 1374–9.
  20. Tack J., Broekaert D., Fischler B. et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome // Gut. – 2006; 55: 1095–103. DOI: 10.1136/gut.2005.077503.
  21. Аведисова А.С. Венлафаксин (велаксин): результаты международных исследований антидепрессанта III поколения // Психиат. и психофармакотер. – 2006; 11 (2): 2–7 [Avedisova A.S. Venlafaksin (velaksin): rezul'taty mezhdunarodnykh issledovanii antidepressanta III pokoleniya // Psikhiatr. i psikhofarmakoter. – 2006; 11 (2): 2–7 (in Russ.)].
  22. Вазагаева Т.И., Федорова А.И. Применение венлафаксина при лечении коморбидных депрессивных и тревожных расстройств // Соц. и клин. психиатр. – 2017; 27 (4): 47–52 [Vazagayeva T.I., Fedorova A.I. Venlafaxine in the treatment of comorbid depressive and anxious disorders // Sots. i klin. psikhiatr. – 2017; 27 (4): 47–52 (in Russ.)].
  23. Trouvin A., Perrot S., Lloret-Linares C. Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment // Clin. Ther. – 2017; 39 (6): 1104–22. DOI: 10.1016/j.clinthera.2017.05.347.
  24. Hughes S., Hickey L., Donaldson L. et al. Intrathecal Reboxetine Suppresses Evokedand Ongoing Neuropathic Pain Behaviours by Restoring Spinal Noradrenergic Inhibitory Tone // Pain. – 2015; 156: 328–34. DOI: 10.1097/01.j.pain.0000460313.73358.31.
  25. Hajhashemi V., Banafshe H., Minaiyan M. et al. Antinociceptive Effects of Venlafaxine in a Rat Model of Peripheral Neuropathy: Role of alpha 2-Adrenergic Receptors // Eur. J. Pharmacol. – 2014; 738: 230–6. DOI: 10.1016/j.ejphar.2014.04.046.
  26. Schreiber S., Backer M., Pick C. Theantinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms // Neurosci Lett. – 1999; 273 (2): 85–8.
  27. Cegielska-Perun, K., Bujalska-Zadrożny, M., Tatarkiewicz, J. et al. Venlafaxine and neuropathic pain // Pharmacology. – 2013; 91: 69–76. DOI: 10.1159/000345035.
  28. Bohren Y., Tessier L., Megat S. et al. Antidepressants Suppress Neuropathic Pain by a Peripheral β2-Adrenoceptor Mediated Anti-TNFα Mechanism // Neurobiol. Dis. – 2013; 60: 39–50. DOI: 10.1016/j.nbd.2013.08.012.
  29. Lelic D., Fischer I., Olesen A. et al. Venlafaxine and oxycodone effects on human spinal and supraspinal pain processing: a randomized cross-over trial // Eur. J. Neurosci. – 2016; 44 (11): 2966–74. DOI: 10.1111/ejn.13443.
  30. Lelic D., Valeriani M., Fischer I. et al. Venlafaxine and oxycodone have different effects on spinal and supraspinal activity in man: a somatosensory evoked potential study // Br. J. Clin. Pharmacol. – 2017; 83 (4): 764–76. DOI: 10.1111/bcp.13177.
  31. Aiyer R., Barkin R., Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review // Pain Med. – 2017; 18 (10): 1999–2012. DOI: 10.1093/pm/pnw261.
  32. Rowbotham M., Goli V., Kunz N. et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study // Pain. – 2004; 110 (3): 697–706. Erratum in: Pain. – 2005; 113 (1–2): 248. DOI: 10.1016/j.pain.2004.05.010.
  33. Jia H., Li Q., Song D. et al. Effects of Venlafaxine and Carbamazepine for Painful Peripheral Diabetic Neuropathy: A Randomized, Double-Blind and Double-Dummy, Controlled Multi-Center Trial // Chin. J. Evid-Based Med. – 2006; 6: 321–8.
  34. Razazian N., Baziyar M., Moradian N. et al. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial // Neurosciences (Riyadh). – 2014; 19 (3): 192–8.
  35. Simpson D. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy // J. Clin. Neuromuscul. Dis. – 2001; 3 (2): 53–62.
  36. Kadiroglu A., Sit D., Kayabasi H. et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus // J. Diabetes Complications. – 2008; 22 (4): 241–5. DOI: 10.1016/j.jdiacomp.2007.03.010. DOI:10.1016/j.jdiacomp.2007.03.010.
  37. Tasmuth T., Härtel B., Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer // Eur. J. Pain. – 2002; 6 (1): 17–24. DOI: 10.1053/eujp.2001.0266.
  38. Amr Y., Yousef A. Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain // Clin. J. Pain. – 2010; 26 (5): 381–5. DOI: 10.1097/AJP.0b013e3181cb406e.
  39. Reuben S., Makari-Judson G., Lurie S. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomypainsyndrome // J. Pain Symptom Manage. – 2004; 27 (2): 133–9. Retraction in: J. Pain Symptom Manage. – 2009; 37 (5): 941. DOI: 10.1016/j.jpainsymman.2003.06.004.
  40. Durand J., Deplanque G., Montheil V.et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial // Ann. Oncol. – 2012; 23 (1): 200–5. DOI: 10.1093/annonc/mdr045.
  41. Kus T., Aktas G., Alpak G., et al. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study // Support Care Cancer. – 2016; 24 (5): 2085–91. DOI: 10.1007/s00520-015-3009-x.
  42. Richards J., Bombardier C., Wilson C. et al. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial // Arch. Phys. Med. Rehabil. – 2015; 96 (4): 680–9. DOI:10.1016/j.apmr.2014.11.024.
  43. Eardley W., Toth C. An openlabel, nonrandomized comparison of venlafaxine and gabapentin as monotherapyor adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy // J. Pain Res. – 2010; 3: 33–49.
  44. Sindrup S., Bach F., Madsen C. et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial // Neurology. – 2003; 60 (8): 1284–9. DOI: 10.1212/01.WNL.0000058749.49264.BD.
  45. Zissis N., Harmoussi S., Vlaikidis N. et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache // Cephalalgia. – 2007; 27 (4): 315–24. DOI: 10.1111/j.1468-2982.2007.01300.x.
  46. Ozyalcin S., Talu G., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine // Headache. – 2005; 45 (2): 144–52. DOI: 10.1111/j.1526-4610.2005.05029.x.
  47. Bulut S., Berilgen M., Baran A. et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study // Clin. Neurol. Neurosurg. – 2004; 107 (1): 44–8. DOI: 10.1016/j.clineuro.2004.03.004.
  48. Lee H., Kim J., Min B. et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial // Am. J. Gastroenterol. – 2010; 105 (7): 1504–12. DOI: 10.1038/ajg.2010.82.
  49. Forssell H., Tasmuth T., Tenovuo O. et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial // J. Orofac. Pain. – 2004; 18 (2): 131–7.
  50. Dwight M., Arnold L., O'Brien H. et al. An open clinical trial of venlafaxine treatment of fibromyalgia // Psychosomatics. – 1998; 39 (1): 14–7. DOI: 10.1016/S0033-3182(98)71375-1.
  51. Diaz-Marsá M., Palomares N., Morón M. et al. Psychological factors affecting response to antidepressant drugs in fibromyalgia // Psychosomatics. – 2011; 52 (3): 237–44. DOI: 10.1016/j.psym.2010.12.014.
  52. Sayar K., Aksu G., Ak I. et al. Venlafaxine treatment of fibromyalgia // Ann. Pharmacother. – 2003; 37 (11): 1561–5. DOI: 10.1345/aph.1D112.
  53. Zijlstra T., Barendregt P., van De Laar M. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial // Arthritis Rheum. – 2002; 46: S105.
  54. Moulin D., Boulanger A., Clark A. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society // Pain Res. Manag. – 2014; 19 (6): 328–35. DOI: 10.1155/2014/754693.
  55. Gharibian D., Polzin J., Rho J. Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy // Clin. J. Pain. – 2013; 29 (5): 377–81. DOI: 10.1097/AJP.0b013e31825e45d9.